Enzyme Modulators
Enzyme modulators are compounds that can enhance or inhibit the activity of enzymes, thereby regulating the rate of biochemical reactions. These modulators play a critical role in controlling metabolic pathways, cell signaling, and various physiological processes. Enzyme modulators are widely used in research and drug development to study enzyme functions and to develop therapeutic agents. At CymitQuimica, we offer a comprehensive range of high-quality enzyme modulators to support your research in enzyme regulation and drug discovery.
Subcategories of "Enzyme Modulators"
Found 693 products of "Enzyme Modulators"
Sort by
Purity (%)
0
100
|
0
|
50
|
90
|
95
|
100
YPSPV (EYGF-33)
During extraction of lecithin from egg yolk, peptide by-products can be isolated and purified by gel filtration. Within the by-products this has led to the discovery of biologically active value-added products. The egg yolk gel filtration (EFGF) fractions were analysed for their antioxidant and angiotensin converting enzyme (ACE) inhibitory activities. EYGF-33 predominantly contained 3 peptides - KLSDW, YPSPV, and MPVHTDAD). YPSPV in EYGF-33 was found to have minimal antioxidant activity. However, YPSPV showed notably high angiotensin converting enzyme (ACE) inhibitory activity, it exceeded the positive control captopril.Purity:Min. 95%Molecular weight:560.3 g/molNitazoxanide - Bio-X ™
CAS:Nitazoxanide acts as a noncompetitive inhibitor of the pyruvate: ferredoxin/flavodoxin oxidoreductases of various microorganism with Ki values between 2 and 10 μM. Nitazoxanide is clinically relevant for its broad-spectrum action to reduce the growth of bacteria, various parasites, and especially for its efficacy against the pathogen Helicobacter pylori. Nitazoxanide also has been shown to be effective in treating inflammatory bowel disease and acute enteritis caused by bacteria. In 2021, nitazoxanide was tested for the treatment of COVID-19 patients with mild symptoms due to its broad antiviral action.Formula:C12H9N3O5SPurity:Min. 90 Area-%Color and Shape:PowderMolecular weight:307.28 g/mol4-5-(4-Pyridylmethylamino)pyrazolo1,5-apyrimidin-3-ylbenzamide
CAS:Selective inhibitor of the mutated RET variant RETV804M, which is the anticipated drug-resistant RET mutant that can occur in tumours treated with kinase inhibitors. The compound has a biochemical IC50 of 0.02 µM and selectivity for purified RETV804M over purified RET and KDR of 3.7 and 110, respectively. The efficacy of the compound was shown also in cell cultures with IC50 of 4.4 µM, and cell assay selectivity for RETV804M over RET and KDR of 0.89 and 2.3, respectively.Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:344.37 g/molA 1070722
CAS:High affinity inhibitor of glycogen synthase kinase GSK-3 with Ki of 0.6 nM. A 1070722 showed favourable characteristics for the penetration across blood brain barrier. A 1070722 was also shown to reduce the phosphorylation of microtubule-associated protein Tau.Formula:C17H13F3N4O2Purity:Min. 95%Color and Shape:SolidMolecular weight:362.31 g/molNintedanib ethanesulfonate
CAS:Used for treatment of idiopathic pulmonary fibrosisFormula:C31H33N5O4•C2H6O3SPurity:Min. 98 Area-%Color and Shape:PowderMolecular weight:649.76 g/molGSK 1904529A
CAS:Inhibitor of IGF1 receptorFormula:C44H47F2N9O5SPurity:Min. 95%Molecular weight:851.33889Bragsin 2
CAS:Inhibitor of BRAG2-mediated activation of Arf GTP-ase. In vitro experiments showed that Bragsin2 inhibits the Arf GTP-ase activation that is mediated by a nucleotide exchange factor BRAG2 in a membrane-dependent manner. Bragsin2 interacts with the PH domain of BRAG2 protein as well as membrane, which prevents the activation of lipidated Arf. Bragsin2 affects the trans-Golgi network and was shown to affect the tumour sphere in breast cancer cell lines.Formula:C11H6F3NO5Purity:Min. 95%Color and Shape:SolidMolecular weight:289.16 g/molGC376 sodium
CAS:GC 376 is an inhibitor of the main protease Mpro (3CLpro) in coronaviruses as well as picornaviruses. This broad-spectrum antiviral compound has been used as investigational veterinary drug for treatment of feline infectious peritonitis virus (FIPV) infections. Recent studies also showed that GC 376 inhibits the main protease Mpro (3CLpro) from SARS-CoV-2 with IC50 of 0.03 μM and EC50 of 3.37 μM.
Formula:C21H30N3NaO8SPurity:Min. 95 Area-%Color and Shape:White PowderMolecular weight:507.53 g/molSD 0006
CAS:SD 0006 is a small-molecule inhibitor, which is synthesized through specialized chemical processes. It functions by selectively inhibiting the cyclooxygenase-2 (COX-2) enzyme, which plays a significant role in the inflammatory pathway. This inhibition reduces the production of pro-inflammatory prostaglandins, ultimately leading to a decrease in inflammation.Formula:C20H20ClN5O2Purity:Min. 95%Molecular weight:397.86 g/molEverolimus
CAS:mTOR kinase inhibitor; rapamycin analog; immunosuppressantFormula:C53H83NO14Purity:90%Color and Shape:White Off-White PowderMolecular weight:958.23 g/molPerindopril t-butylamine salt - Bio-X ™
CAS:Perindopril t-butylamine salt inhibits the angiotensin converting enzyme (ACE) to prevent the conversion of angiotensin I to angiotensin II. When used in drug formulations, it has been shown to decrease blood pressure in patients with congestive heart failure. Perindopril also has an effect on the renin-angiotensin system, which regulates blood pressure and fluid homeostasis by promoting vasoconstriction and increasing salt and water retention. Perindopril t-butylamine salt is part of our Bio-X ™ Range. These products are aimed at life science researchers who need high quality ready to use products for assay development, screening or other R&D work. With a solubility datasheet and convenient vials, all of our Bio-X ™ products are in stock across our global warehouses for rapid delivery and ease of use.Formula:C23H43N3O5Purity:Min. 98 Area-%Color and Shape:PowderMolecular weight:441.61 g/molGDC 0032
CAS:Inhibitor of PI3K kinase isoforms α, δ, and γFormula:C24H28N8O2Purity:Min. 95%Molecular weight:460.53 g/molPitavastatin calcium
CAS:Inhibitor of HMG-CoA reductase
Formula:C50H46F2N2O8CaPurity:Min. 95%Color and Shape:White Off-White PowderMolecular weight:880.98 g/molNiacinamide
CAS:Vitamin B3; antioxidant; favours cell repairFormula:C6H6N2OPurity:98.5 To 101.5 Area-%Color and Shape:White PowderMolecular weight:122.12 g/molFenoprofen calcium
CAS:Inhibitor of COX-1 and COX-2 cyclooxygenasesFormula:C30H26CaO6Purity:Min. 95%Color and Shape:PowderMolecular weight:524.62 g/molPF 06409577
CAS:Potent agonist of a1β1γ1 5′-adenosine monophosphate-activated protein kinase (AMPK). It binds to the allosteric drug and metabolite (ADaM) site at the α- and β- subunit interface of AMPK. It has potential for the treatment of diabetic nephropathy. PF 06409577 reduces infections caused by flaviviruses, mediated by changes in the metabolism of lipids in host cells.
Formula:C19H16ClNO3Purity:Min. 95%Color and Shape:White/Off-White SolidMolecular weight:341.79 g/molAcid alpha-glucosidase (83-99), human
Acid α-glucosidase (83-99) (human) is derived from the exogenous enzyme which degrades glycogen, maltose and isomaltose through targeting alpha -1,4 and alpha -1,6 linkages. Once synthesised in its precursor form, within the Golgi it is glycosylated and acquires mannose 6-phosphate residues. This allows it to be transported to the Lysosome in a multistep process.Pompe disease, also known as glycogen storage disease type II, can be diagnosed through the absence of acid α-glucosidase activity within patients. Therefore glycogen degradation in the lysosome is inhibited by this autosomal recessive disorder. This results in the accumulation of glycogen and tissue destruction, hence contributing to the pathologies of muscle weakness and respiratory failure, associated with infantile onset and adult onset Pompe disease.Purity:Min. 95%Molecular weight:1,844.9 g/molepsilon - PKC Inhibitor
eV1-2 is a selective εPKC inhibitor peptide which interferes with protein-protein interactions between the ϵPKC isozyme and its anchoring protein (ϵRACK). ϵPKC and ϵRACK regulate the contraction rate of heart muscle cells and provide protection from ischemia induced cell death. ϵV1-2 is derived from the C2 domain of ϵPKC, a region important for protein-protein interactions and thus acts as a competitive inhibitor of these interactions. The C2 region is well conserved between species, but different enough from other PKC isozymes to allow for targeted inhibition (ϵV1-2 is 88% identical between sea slugs and rat ϵPKC, yet only 36% identical between rat ϵPKC and rat θ´PKC). This peptide contains a C-terminal cysteine residue for conjugation to a carrier protein.Purity:Min. 95%Color and Shape:PowderMolecular weight:946.5 g/molRoflumilast - Bio-X ™
CAS:Roflumilast is a selective phosphodiesterase-4 inhibitor that is used for the treatment of exacerbations in patients with chronic obstructive pulmonary disease (COPD). It is also used to treat plaque psoriasis. This drug has anti-inflammatory and immunomodulatory effects as it aids in increasing levels of cAMP.
Formula:C17H14Cl2F2N2O3Purity:Min. 95%Color and Shape:PowderMolecular weight:403.21 g/mol
